Drugs / EB-HC01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07641036 | Mar 2026 → Mar 2027 expected | gallbladder carcinoma, intrahepatic cholangiocarcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-HC01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07641036 ↗ |
| Modality | Cell therapy | “allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells” NCT07641036 ↗ |
| Route | Intravenous | “participants receive intravenous EB-HC01 on Days 0 and 7 of a 28-day cycle” NCT07641036 ↗ |
| Target | CEACAM5 | “allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells” NCT07641036 ↗ |